EUCTR2005-003000-11-FI进行中（未招募）1 期
An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg tablets alone or in combination with other antihypertensive medications in patients with hypertension.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •patients aged at least 18 years.
- •diagnosis of essential hypertension (as defined in JNC-7; P03-04405) and taking between one and three antihypertensive medications at a stable dose for at least four weeks before entry to the preceding trial 502.480.
- •blood pressure not adequately controlled on existing antihypertensive treatment before entry to the preceding trial 502.480 .
- •have been shown not to respond to six weeks treatment with T80/H12.5 in the preceding trial 502.480. (Failure to respond defined as seated DBP = 90 mmHg.)
- •are randomised to the preceding trial 502.480 and have completed that trial in the fourteen (14) days prior to Visit 1.
- •willing and able to provide written informed consent (in accordance with Good Clinical Practice and local legislation).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •women of child-bearing potential who are NOT practising acceptable means of birth control or do NOT plan to continue using acceptable means of birth control throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives.
- •women with a positive serum pregnancy test at Visit 1 or at any subsequent visit.
- •women who are breastfeeding.
- •clinically significant change in ECG from baseline that is reported as an adverse event in the preceding 502.480 trial.
- •development of any medical condition in the preceding 502.480 trial that in the investigator's opinion could be worsened by treatment with T80/H25.
- •discontinuation from the preceding 502.480 trial because of any adverse event or any other reason.
- •known or suspected secondary hypertension.
- •mean SBP equal to or greater than 200 mmHg at any visit.
- •severe hepatic impairment (e.g. clinically significant cholestasis, biliary obstructive disorders or hepatic insufficiency).
- •severe renal impairment (known creatinine clearance < 30 mL/min or clinical markers of severe renal impairment).
- •bilateral renal artery stenosis or renal artery stenosis in a solitary kidney.
- •patients post-renal transplant or with only one functioning kidney.
- •clinically relevant hypokalemia or hyperkalemia.
- •uncorrected volume or sodium depletion.
- •primary aldosteronism.
- •hereditary fructose intolerance.
- •patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists.
- •history of drug or alcohol dependency more recent than six months before entry to the preceding 502.480 trial.
- •concurrent participation in another clinical trial or any investigational therapy at any time after thirty days prior to signing the consent form for the preceding 502.480 trial.
- •hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
- •known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other angiotensin-II receptor antagonists or hydrochlorothiazide or sulphonamide-derived drugs.)
- •concomitant therapy with lithium, cholestyramine or colestipol resins.
- •non-compliance with study medication (defined as less than 80% or more than 120%) during the preceding 502.480 trial.
- •any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide.
研究者
相似试验
进行中（未招募）
1 期
An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg tablets alone or in combination with other antihypertensive medications in patients with hypertension.EUCTR2005-003000-11-DKBoehringer Ingelheim Ireland Ltd.480
进行中（未招募）
不适用
An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg tablets alone or in combination with other antihypertensive medications in patients with hypertension.essential hypertensionEUCTR2005-003000-11-DEBoehringer Ingelheim Pharma GmbH & Co.KG480
进行中（未招募）
不适用
An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with other antihypertensive medications in patients with hypertension.EUCTR2005-003000-11-ITBOEHRINGER ING.480
进行中（未招募）
不适用
An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg tablets alone or in combination with other antihypertensive medications in patients with hypertensioessential hypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2007-002422-29-ATBoehringer Ingelheim Austria GmbH687
进行中（未招募）
不适用
An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg tablets alone or in combination with other antihypertensive medications in patients with hypertensioessential hypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2007-002422-29-CZBoehringer Ingelheim687